Medicare Enrolled

Dr. Slavisa Gasic, MD

Hematology & Oncology · San Antonio, TX
Low-engagement
7355 BARLITE BLVD STE 504, San Antonio, TX 78224
2106169922
In practice since 2007 (19 years)
NPI: 1558403337 verify on NPPES ↗
High
DATA COVERAGE
Data in 3 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Gasic from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Gasic? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Gasic

Dr. Slavisa Gasic is a hematology & oncology specialist in San Antonio, TX, with 19 years of NPI registration.

Between the years covered by Open Payments, Dr. Gasic received a total of $4,438 from 33 pharmaceutical and/or device companies across 191 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Gasic is High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice $4,438 industry payments

Industry Payment Transparency

Open Payments through 2020 ↗
$4,438
Total received (2018-2020)
Avg $1,479/year across 3 years
Top 45% in TX for hematology & oncology
33
Companies
191
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$4,220 (95.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$217 (4.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2020
$15
2019
$1,997
2018
$2,425

Payments by company (2020)

Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$538
E.R. Squibb & Sons, L.L.C.
$405
Takeda Pharmaceuticals U.S.A., Inc.
$368
Merck Sharp & Dohme Corporation
$316
Incyte Corporation
$256
Novartis Pharmaceuticals Corporation
$255
Astellas Pharma US Inc
$223
Bayer HealthCare Pharmaceuticals Inc.
$206
PFIZER INC.
$198
Janssen Biotech, Inc.
$191
Seattle Genetics, Inc.
$185
Ipsen Biopharmaceuticals, Inc
$138
Teva Pharmaceuticals USA, Inc.
$133
Lilly USA, LLC
$124
Amgen Inc.
$122
AbbVie, Inc.
$100
TESARO, Inc.
$88
GENZYME CORPORATION
$76
Exelixis Inc.
$61
TerSera Therapeutics LLC
$59
Pharmacyclics LLC, An AbbVie Company
$57
Boehringer Ingelheim Pharmaceuticals, Inc.
$57
Genentech USA, Inc.
$53
AMAG Pharmaceuticals, Inc.
$43
Celgene Corporation
$35
EMD Serono, Inc.
$32
JAZZ PHARMACEUTICALS INC.
$21
Lexicon Pharmaceuticals, Inc.
$21
Daiichi Sankyo Inc.
$20
Gilead Sciences, Inc.
$15
Eisai Inc.
$15
EISAI INC.
$14
Verastem, Inc.
$14
Top 3 companies account for 29.5% of total payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · Alecensa · Aliqopa · BENDEKA · BOSULIF · Bavencio · CALQUENCE · CYRAMZA · Cabometyx · Copiktra · DARZALEX · EMEND · EMPLICITI · ERBITUX · Erleada · FERAHEME · GILOTRIF · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INJECTAFER · Imbruvica · JADENU · JAKAFI · JEVTANA · KEYTRUDA · Kyprolis · LYNPARZA · Lenvima · MVASI · MYLOTARG · NINLARO · Neulasta · Nplate · OPDIVO · Onivyde · PIQRAY · PROMACTA · Perjeta · RYDAPT · Revlimid · SOMATULINE DEPOT · Stivarga · VOTRIENT · VYXEOS · Venclexta · Vitrakvi · XOSPATA · XTANDI · ZEJULA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (95%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Looking for a hematology & oncology specialist in San Antonio?
Compare hematology & oncology specialists in the San Antonio area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncology specialists nearby

Geographic Context

Hematology & oncology specialists within 10 mi
56
Per 100K population
2.7
County median income
$70,571
Nearest hospital
CHILDREN'S HOSPITAL OF SAN ANTONIO
7.8 mi

Data Sources

Provider Registry ✓ NPPES Weekly updates
Medicare Enrollment ✓ PECOS Monthly updates
Practice Data — No data N/A
Industry Payments ✓ Open Payments CY 2020
Disciplinary History — Not public N/A

This provider has data in 3 of 4 available federal datasets, with a Data Coverage level of High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Gasic is a hematology & oncology specialist, with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Does Dr. Gasic receive payments from pharmaceutical companies?
Yes. Dr. Gasic received a total of $4,438 from 33 companies across 191 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
What does Data Coverage mean?
Data Coverage (currently High for Dr. Gasic) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →

Explore related providers

Same specialty & city
Hematology & Oncology Specialists in San Antonio
Browse hematology & oncology specialists in San Antonio ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in TX
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in TX
Which TX hematology & oncology specialists receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Takeda Pharmaceuticals U.S.A., Inc. Payments to Doctors
See all physicians who received payments from Takeda Pharmaceuticals U.S.A., Inc.
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →